Major study on DiagnoCure's GCC biomarker published in Jama



    
         - Results demonstrate that GCC is the strongest independent
                 predictor of colorectal cancer recurrence -

    Ticker Symbol: CUR
    

    QUEBEC CITY, QC and WEST CHESTER, PA, Feb. 17 /CNW Telbec/ - The Journal
of the American Medical Association (JAMA), Vol. 301, No.7, this week
published positive results from a major prospective 5-year multicenter study
of over 400 enrolled patients demonstrating that guanylyl cyclase C (GCC) is
the strongest independent predictor of colorectal cancer recurrence in
patients considered low risk by current assessment methods. The study was
conducted by investigators from Thomas Jefferson University, with
contributions from McGill University, the Fox Chase Cancer Center and others.
DiagnoCure Inc. owns the exclusive worldwide diagnostic rights to the GCC
biomarker, and since last September has offered the Previstage(TM) GCC test to
physicians and patients from its Pennsylvania-based service laboratory.
    GCC is a gene coding for a protein which is expressed in colorectal
cells, both normal and cancerous, but is never found in normal tissue in other
parts of the body. When GCC is detected in lymph nodes removed during
colorectal cancer surgery, it is an indication of the presence of colorectal
cancer metastases.
    The study's principal investigator, Dr. Scott Waldman, Chairman of the
Department of Pharmacology and Experimental Therapeutics at Thomas Jefferson
University, stated "Patients with cancer cells in their regional lymph nodes
carry a worse prognosis and a higher risk of recurrence; detecting GCC in the
patient lymph nodes could be useful for identifying patients who might benefit
from treatment with adjuvant chemotherapy."
    In a group of 257 colorectal cancer (CRC) patients who were thought to
have a lower risk of recurrence according to histopathology (stage I and II
patients), when GCC was considered independently from other factors, patients
whose nodes were GCC positive were 4.7 times more likely to develop disease
recurrence than those whose nodes were GCC negative, and 3.3 times more likely
to die within three years. In fact, patients with GCC positive nodes had a
risk of recurrence and survival rate comparable to that of patients considered
higher risk by histopathology (stage III).
    Currently, most patients who are considered to have a lower risk of
recurrence by histopathology do not receive adjuvant treatment, such as
chemotherapy, after their surgery. However, it is widely recognized that
histopathology, which consists of microscopically examining thin slices of the
lymph nodes, is imperfect and up to 30% of histopathology node-negative
patients experience disease recurrence and face greater risk of death.
Guanylyl cyclase C is the first validated marker useful in detecting the
presence or absence of CRC cells in the regional lymph nodes, using a
technology that is 100,000 times more sensitive than the current microscopic
method. With GCC testing, patients who are most likely to experience CRC
recurrence can receive appropriate treatment, while those who are at lower
risk of disease recurrence can avoid the negative side effects of treatment.
    "The results from this study, published in the peer-reviewed Journal of
the American Medical Association, provide strong evidence that GCC matters
when it comes to predicting the risk of colorectal cancer recurrence and is a
major advance for the individualized treatment of colorectal cancer patients.
With our very sensitive GCC-based test, physicians and their patients now have
an opportunity to use the latest genomic technology to help them make the best
possible treatment decisions," said John Schafer, President and CEO of
DiagnoCure.
    Every year in North America, 174,000 people are diagnosed with colorectal
cancer and 61,000 die from it.

    About Previstage(TM) GCC Colorectal Cancer Staging Test

    Previstage(TM) GCC Colorectal Cancer Staging Test is the first test that
can molecularly assess the presence or absence of CRC cells in the lymph nodes
removed during the surgery. The test is a laboratory-developed proprietary
assay that detects in lymph nodes the expression or absence of expression of
the GCC marker. When GCC is expressed in the lymph nodes, it is an indication
of the presence of colorectal cancer metastases, and hence an indication of
higher risk of disease recurrence. Knowing the lymph nodes status can help
physicians and patients make optimal treatment decisions. The test was
launched in 2008 and is exclusively performed by DiagnoCure Oncology
Laboratories, a CLIA-certified service laboratory, located in West Chester,
Pennsylvania.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, DiagnoCure Oncology Laboratories, a subsidiary of
DiagnoCure Inc., launched the Previstage(TM) GCC Colorectal Cancer Staging
Test, the first GCC-based molecular test for the management of colorectal
cancer. The Company also has a strategic alliance with Gen-Probe (NASDAQ:  
GPRO) for the development and commercialization of a second-generation
prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker.
This test is also available through laboratories in the U.S. using PCA3
analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked
PROGENSA(TM) PCA3 in vitro assay, and in Canada. For more information, visit
www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF




For further information:

For further information: Investors: J.F. Bureau, CFA, Sr. Vice President
and CFO, DiagnoCure Inc., (418) 527-6100, communications@diagnocure.com;
Media: Canada: Jean-Pierre Trudel and Associates, (514) 347-6111,
jp.trudel@videotron.ca; U.S.: Karen Sparks, Mentus Life Sciences, (858)
455-5500, Karen@mentus.com

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890